Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis-Reference-Cited by-同舟云学术

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

Published:2022-08-27 Issue:11 Volume:97 Page:1413-1418
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Jabbour Elias¹^ORCID,Sasaki Koji¹^ORCID,Haddad Fadi G.¹^ORCID,Issa Ghayas C.¹^ORCID,Skinner Jeffrey¹,Dellasala Sara¹,Yilmaz Musa¹^ORCID,Ferrajoli Alessandra¹,Bose Prithviraj¹^ORCID,Thompson Philip¹,Alvarado Yesid¹,Jain Nitin¹,Garcia‐Manero Guillermo¹^ORCID,Takahashi Koichi¹,Borthakur Gautam¹^ORCID,Pemmaraju Naveen¹^ORCID,Pierce Sherry¹,Kantarjian Hagop¹^ORCID

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26689

Reference23 articles.

1. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

2. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

3. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia